FOX04-DRI 5mg
FOX04-DRI is a D-retro-inverso peptide designed to disrupt the FOXO4-p53 protein-protein interaction that maintains cellular senescence. In the landmark 2017 Cell paper by Baar et al., treatment of naturally aged mice with FOXO4-DRI selectively induced apoptosis in senescent cells, resulting in restored fitness, fur density, and renal function.
Sequence
D-retro-inverso of FOXO4 p53 interaction domain
Market avg: $179.99 — save 45%
Volume pricing
Pay with USDC via Coinbase Commerce
Certificate of Analysis
Independently verified by Janoshik Analytical
Test ID
JAN-FOX04-2026-001
Purity
96.3%
Method
HPLC-MS
Batch
FOX-2026-01A
Test Date
January 20, 2026
Identity
Confirmed
Storage Requirements
Lyophilized
-20°C recommended, protect from light
Reconstituted
-20°C in aliquots, avoid freeze-thaw cycles
D-amino acid peptide with enhanced protease resistance. Store desiccated at -20°C for maximum stability.
Published Research
2 peer-reviewed studies
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
Baar MP, Brandt RM, Putavet DA, et al. — Cell, 2017
Seminal paper demonstrating that FOXO4-DRI peptide selectively induces apoptosis of senescent cells in vivo.
Senescence and the SASP: Many Therapeutic Avenues
Gorgoulis V, Adams PD, Alimonti A, et al. — Genes & Development, 2019
Review covering senescence biology and therapeutic strategies including peptide-based senolytics like FOXO4-DRI.
Research use only. All products are sold strictly for in-vitro research purposes only. Not for human consumption. Information provided references published research literature. No medical claims are made or implied.